Nurix Therapeutics (NRIX) reported fiscal third-quarter 2026 revenue of $673.1 million and net income of $549.8 million, compared with revenue of $7.9 million and a net loss of $86.4 million a year earlier. Diluted earnings per share were $4.73, versus a loss of $1.03 per share.
The quarter included $653.2 million of license revenue from Nurix’s collaboration with Roche and a $10.0 million Sanofi development milestone. Cash, cash equivalents and marketable securities totaled $1.1 billion as of August 31, 2026.
- Nurix dosed the first patient in the Phase 3 DAYBreak CLL-306 trial of bexobrutideg versus pirtobrutinib in relapsed or refractory CLL/SLL.
- The company began recruiting for the Phase 1b/2 NX-5948-203 combination study in CLL/SLL.
- Research and development expense was $79.3 million, down from $86.1 million a year earlier.
- General and administrative expense was $34.4 million, compared with $13.2 million a year earlier.
- Nurix advanced NX-1607 into Phase 1b expansion cohorts in MSS colorectal cancer, NSCLC, CRPC and melanoma.
$NRIX Insider Trading Activity
$NRIX insiders have traded $NRIX stock on the open market 24 times in the past 6 months. Of those trades, 0 have been purchases and 24 have been sales.
Here’s a breakdown of recent trading of $NRIX stock by insiders over the last 6 months:
- CHRISTINE RING (Chief Legal Officer) has made 0 purchases and 11 sales selling 96,856 shares for an estimated $2,012,771.
- GWENN HANSEN (Chief Scientific Officer) has made 0 purchases and 7 sales selling 22,374 shares for an estimated $497,355.
- HOUTE HANS VAN (Chief Financial Officer) has made 0 purchases and 6 sales selling 24,049 shares for an estimated $455,581.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NRIX Hedge Fund Activity
We have seen 106 institutional investors add shares of $NRIX stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RUBRIC CAPITAL MANAGEMENT LP added 4,753,893 shares (+192.2%) to their portfolio in Q2 2026, for an estimated $115,329,444
- REDMILE GROUP, LLC removed 3,659,021 shares (-47.3%) from their portfolio in Q2 2026, for an estimated $88,767,849
- COMMODORE CAPITAL LP removed 2,275,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $55,191,500
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,146,354 shares (+65.2%) to their portfolio in Q2 2026, for an estimated $52,070,548
- DEUTSCHE BANK AG\ removed 2,143,571 shares (-93.4%) from their portfolio in Q2 2026, for an estimated $52,003,032
- VESTAL POINT CAPITAL, LP added 1,550,000 shares (+23.8%) to their portfolio in Q2 2026, for an estimated $37,603,000
- LONGAEVA PARTNERS L.P. removed 1,490,202 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $36,152,300
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
